Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis

Pieris Pharmaceuticals logo

About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)

Advanced Chart

Key Stats

Today's Range
$13.26
$15.35
50-Day Range
$13.60
$17.07
52-Week Range
$6.20
$18.68
Volume
51,728 shs
Average Volume
64,171 shs
Market Capitalization
$17.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Pieris Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

PIRS MarketRank™: 

Pieris Pharmaceuticals scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Pieris Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pieris Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pieris Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pieris Pharmaceuticals has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for PIRS.
  • Dividend Yield

    Pieris Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Pieris Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for PIRS.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Pieris Pharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pieris Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.39% of the stock of Pieris Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    40.11% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pieris Pharmaceuticals' insider trading history.
Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

Pieris Pharmaceuticals Inc
Palvella Therapeutics Inc (PVLA)
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
One new option listing and one option delisting on December 16th
See More Headlines

PIRS Stock Analysis - Frequently Asked Questions

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($19.20) EPS for the quarter, hitting the consensus estimate of ($19.20). The biotechnology company earned $4.06 million during the quarter, compared to analysts' expectations of $7.98 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 80.93% and a negative net margin of 39.71%.

Pieris Pharmaceuticals's stock reverse split on Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Adobe (ADBE), GE Aerospace (GE) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/02/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PIRS
Employees
140
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,540,000.00
Pretax Margin
-1,179.96%

Debt

Sales & Book Value

Annual Sales
$42.81 million
Price / Cash Flow
N/A
Book Value
$21.66 per share
Price / Book
0.63

Miscellaneous

Free Float
1,236,000
Market Cap
$17.95 million
Optionable
Optionable
Beta
0.61

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:PIRS) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners